Lexaria Bioscience: Patented Technology for Rapid Drug Delivery

A leading bioscience company with patented technology

Lexeria is a leading bioscience company. It began developing its DehydraTECH™ technology in 2014 and has since strengthened and broadened the technology to an unprecedented degree. Lexaria is a global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs. “In many instances, we’ve reduced the amount of time from 90 or 120 minutes down to as little as five or 10 minutes, ” says Chairman & CEO, Chris Bunka.

Lexaria  has also demonstrated early-stage effectiveness in improving delivery through human skin. This would be for the potential development of topically-administered products, including patches, creams and lotions.

The company’s technology is also currently being evaluated for improved delivery characteristics of antiviral drugs in the fight against COVID-19.

Moreover, Lexaria operates four subsidiary companies to focus on its different commercial opportunities in their respective industries: Lexaria Pharma Corp. investigating new products for hypertension, anti-viral treatments and other drug classes; Lexaria Nicotine Corp. (16.67% owned by Altria Ventures Inc) investigating oral non-combusted tobacco-derived nicotine product formats; Lexaria Hemp Corp. pursuing business-to-business opportunities with cannabinoids such as cannabidiol from hemp; and Lexaria Canpharm Corp. operating a state-of-the-art Health Canada licensed laboratory capable of developing novel psychotropic cannabinoid formulations for potential commercialization in that sector where federally legal to do so.  The Lexaria companies sub-license the company’s DehydraTECH technology worldwide for the delivery of fat-soluble active molecules and drugs.

Lexaria expects 2021 to be their busiest year for R & D, with a particular focus on the effective delivery of antiviral drugs and CBD for hypertension.

For more information on Lexaria Bioscience Corp. (NASDAQ: LEXX) please click on the request investor info button.